Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid

• Status: Completed
• Trial end date: 2005-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to assess bone mineral density in patients switching from an oral bisphosphonate to zoledronic acid, compared to those staying on the oral bisphosphonate.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Diphosphonates; Zoledronic Acid

Criteria

Inclusion Criteria:

• Post-menopausal women between 45 and 79 years of age

• Must be osteopenic/osteoporotic

• Treatment with oral bisphosphonate for at least 1 year

Exclusion Criteria:

• Any woman of child bearing potential

• Treatment with other bone active agents

Other protocol-defined inclusion/exclusion criteria may apply.